Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOMERICA INCBMRA · Entity 8171 | Director | December 13, 2023 | December 14, 2023 |
| NEOGENOMICS INCNEO · Entity 2096 | Director | June 01, 2026 | June 03, 2026 |
| ORASURE TECHNOLOGIES INCOSUR · Entity 6152 | Director | September 06, 2026 | September 09, 2026 |
| Quantum-Si IncQSI · Entity 6440 | Director | May 18, 2026 | May 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOMERICA INC
Report date December 13, 2023 · Filed December 14, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-qualified stock optionSEC Table II · derivative / convertible security · Conversion / exercise price $1.01 · Expires 2034-12-13 | Direct | 75,000 |
Reported balance
After 2023-12-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-12-13 · Grant · Acquired 75,000 · Balance 75,000 F1: Options granted to Ms. Coste as part of her Fiscal 2024 Board compensation package. F2: Not Applicable |
| Common stockSEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2023-12-13 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: Options granted to Ms. Coste as part of her Fiscal 2024 Board compensation package.
F2: Not Applicable
NEOGENOMICS INC
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,893 |
Reported balance
After 2026-06-01 transaction · row 1
1 source rowRow 1 · 2026-06-01 · Exercise / conversion · Acquired 5,893 · Balance 5,893 F1: Reflects release of restricted stock units that were previously reported on a Form 4. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-06-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-01 · Exercise / conversion · Disposed 5,893 · Balance 0 F2: Once vested, the shares of common stock are not subject to expiration. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 15,970 |
Reported balance
After 2026-06-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-01 · Grant · Acquired 15,970 · Balance 15,970 F2: Once vested, the shares of common stock are not subject to expiration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.52 · Expires 2036-06-01 | Direct | 11,069 |
Reported balance
After 2026-06-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-01 · Grant · Acquired 11,069 · Balance 11,069 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.76 · Expires 2036-01-01 | Direct | 4,171 |
Reported balance
Holding disclosure · report date 2026-06-01 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 4,171 |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects release of restricted stock units that were previously reported on a Form 4.
F2: Once vested, the shares of common stock are not subject to expiration.
ORASURE TECHNOLOGIES INC
Report date September 06, 2026 · Filed September 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 204,598 |
Reported balance
After 2026-09-06 transaction · row 1
1 source rowRow 1 · 2026-09-06 · Tax withholding · Disposed 5,116 · Balance 204,598 F1: Withholding of shares to pay the tax liability associated with vesting of restricted shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Withholding of shares to pay the tax liability associated with vesting of restricted shares.
Quantum-Si Inc
Report date May 18, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.85 · Expires 2036-05-18 | Direct | 251,185 |
Reported balance
After 2026-05-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-18 · Grant · Acquired 251,185 · Balance 251,185 F1: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to continued service through the applicable vesting date. |
| Class A Common StockSEC Table I · non-derivative | Direct | 114,285 |
Reported balance
Holding disclosure · report date 2026-05-18 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 114,285 |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to continued service through the applicable vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MERIDIAN BIOSCIENCE INC
Report date January 31, 2023 · Filed January 31, 2023
Section 16 reporting ended · disclosed 2023-01-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2023-01-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-01-31 · Grant · Acquired 47,060 · Balance 267,651 F1: Represents 47,060 shares of the Issuer's common stock awarded to the Reporting Person upon the vesting of a portion of an award of performance stock units ("PSUs") in connection with the closing of the transactions contemplated by the Merger Agreement (as defined below). Row 2 · 2023-01-31 · Disposition to issuer · Disposed 267,651 · Balance 0 F2: The shares were disposed of pursuant to the Agreement and Plan of Merger dated as of July 7, 2022 (the "Merger Agreement") by and among the Issuer and SD Biosensor, Inc., a corporation with limited liability organized under the laws of the Republic of Korea whereby, immediately prior to the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were converted into the right to receive $34.00 per share in cash and, when so converted, automatically cancelled. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.10 · Expires 2029-11-05 | Direct | 0 |
Reported balance
After 2023-01-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-01-31 · Disposition to issuer · Disposed 66,039 · Balance 0 F3: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.48 · Expires 2030-11-05 | Direct | 0 |
Reported balance
After 2023-01-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-01-31 · Disposition to issuer · Disposed 83,535 · Balance 0 F4: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.88 · Expires 2031-11-04 | Direct | 0 |
Reported balance
After 2023-01-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-01-31 · Disposition to issuer · Disposed 82,940 · Balance 0 F5: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 47,060 shares of the Issuer's common stock awarded to the Reporting Person upon the vesting of a portion of an award of performance stock units ("PSUs") in connection with the closing of the transactions contemplated by the Merger Agreement (as defined below).
F2: The shares were disposed of pursuant to the Agreement and Plan of Merger dated as of July 7, 2022 (the "Merger Agreement") by and among the Issuer and SD Biosensor, Inc., a corporation with limited liability organized under the laws of the Republic of Korea whereby, immediately prior to the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were converted into the right to receive $34.00 per share in cash and, when so converted, automatically cancelled.
F3: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.
F4: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.
F5: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 16, 2021 Filed Feb 17, 2021 10:14 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Exercise / conversionCommon Stock | 2,082 | $10.10 | $21,028.20 |
DisclosureSEC source: 0001127602-21-006067 · form4.xml · nonDerivative · entry 1 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2021 Filed Feb 16, 2021 08:45 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Exercise / conversionStock Options (Right to Buy) · Derivative | 23,097 | $0.00 Strike: $10.10 | $0.00 |
DisclosureSEC source: 0001127602-21-005607 · form4.xml · derivative · entry 6 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,724 Underlying: Common Stock · 23,097 shares Expires 2029-11-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · kind: The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective September 15, 2020. F6 · derivative.exercise_date: These non-qualified options were awarded under the 2012 Stock Incentive Plan pursuant to Mr. Kenny's Amended and Restated Employment Agreement effective October 1, 2019. The options vest on a pro rata basis over the three (3) years from the Agreement's effective date. Read SEC document |
| February 12, 2021 Filed Feb 16, 2021 08:45 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | SaleCommon Stock | 26,181 | $30.14 | $789,084.87 |
DisclosureSEC source: 0001127602-21-005607 · form4.xml · nonDerivative · entry 4 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,936 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective September 15, 2020. F4 · price: Prices range from $30.00 per share to $30.49 per share. The reporting person undertakes to provide full pricing information if requested by the Securities and Exchange Commission, the issuer or a security holder of the issuer. Read SEC document |
| February 12, 2021 Filed Feb 16, 2021 08:45 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Exercise / conversionCommon Stock | 23,097 | $10.10 | $233,279.70 |
DisclosureSEC source: 0001127602-21-005607 · form4.xml · nonDerivative · entry 3 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 08:45 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Exercise / conversionStock Options (Right to Buy) · Derivative | 1,164 | $0.00 Strike: $10.10 | $0.00 |
DisclosureSEC source: 0001127602-21-005607 · form4.xml · derivative · entry 5 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,821 Underlying: Common Stock · 1,164 shares Expires 2029-11-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective September 15, 2020. F6 · derivative.exercise_date: These non-qualified options were awarded under the 2012 Stock Incentive Plan pursuant to Mr. Kenny's Amended and Restated Employment Agreement effective October 1, 2019. The options vest on a pro rata basis over the three (3) years from the Agreement's effective date. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 08:45 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | SaleCommon Stock | 1,320 | $30.00 | $39,601.45 |
DisclosureSEC source: 0001127602-21-005607 · form4.xml · nonDerivative · entry 2 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,020 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective September 15, 2020. F2 · price: Prices range from $30.00 per share to $30.015 per share. The reporting person undertakes to provide full pricing information if requested by the Securities and Exchange Commission, the issuer or a security holder of the issuer. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 08:45 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Exercise / conversionCommon Stock | 1,164 | $10.10 | $11,756.40 |
DisclosureSEC source: 0001127602-21-005607 · form4.xml · nonDerivative · entry 1 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,340 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 13:22 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Exercise / conversionStock Options (Right to Buy) · Derivative | 16,134 | $0.00 Strike: $10.10 | $0.00 |
DisclosureSEC source: 0001127602-21-004878 · form4.xml · derivative · entry 5 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,985 Underlying: Common Stock · 16,134 shares Expires 2029-11-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective September 15, 2020. F6 · derivative.exercise_date: These non-qualified options were awarded under the 2012 Stock Incentive Plan pursuant to Mr. Kenny's Amended and Restated Employment Agreement effective October 1, 2019. The options vest on a pro rata basis over the three (3) years from the Agreement's effective date. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 13:22 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Exercise / conversionStock Options (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $14.50 | $0.00 |
DisclosureSEC source: 0001127602-21-004878 · form4.xml · derivative · entry 4 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-10-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective September 15, 2020. F4 · derivative.exercise_date: These non-qualified options were awarded under the 2012 Stock Incentive Plan and vest in four equal installments from the date of grant until fully vested on October 9, 2021. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 13:22 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | SaleCommon Stock | 68,288 | $29.86 | $2,039,113.82 |
DisclosureSEC source: 0001127602-21-004878 · form4.xml · nonDerivative · entry 3 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,176 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective September 15, 2020. F2 · price: Prices range from $25.26 per share to $30.35 per share. The reporting person undertakes to provide full pricing information if requested by the Securities and Exchange Commission, the issuer or a security holder of the issuer. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 13:22 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Exercise / conversionCommon Stock | 16,134 | $10.10 | $162,953.40 |
DisclosureSEC source: 0001127602-21-004878 · form4.xml · nonDerivative · entry 2 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,464 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 13:22 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Exercise / conversionCommon Stock | 50,000 | $14.50 | $725,000.00 |
DisclosureSEC source: 0001127602-21-004878 · form4.xml · nonDerivative · entry 1 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,330 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2021 Filed Feb 8, 2021 10:18 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | SaleCommon Stock | 20,000 | $25.00 | $500,000.00 |
DisclosureSEC source: 0001127602-21-004268 · form4.xml · nonDerivative · entry 2 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,330 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective November 9, 2020. Read SEC document |
| February 05, 2021 Filed Feb 8, 2021 10:18 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | SaleCommon Stock | 20,000 | $25.00 | $500,000.00 |
DisclosureSEC source: 0001127602-21-004268 · form4.xml · nonDerivative · entry 1 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,330 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective September 15, 2020. Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 13:29 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantStock Options (Right to Buy) · Derivative | 83,535 | $0.00 Strike: $18.48 | $0.00 |
DisclosureSEC source: 0001127602-20-028458 · form4.xml · derivative · entry 2 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,535 Underlying: Common Stock · 83,535 shares Expires 2030-11-05 F2 · derivative.exercise_date: These options are awarded under the 2012 Stock Incentive Plan and vest in full (100%) on 11/15/2023. Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 13:29 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantCommon Stock | 56,006 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-028458 · form4.xml · nonDerivative · entry 1 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,330 F1 · shares: These restricted stock units are awarded under the 2012 Stock Incentive Plan and vest in full (100%) on 11/15/2023. Read SEC document |
| March 12, 2020 Filed Mar 13, 2020 09:05 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | PurchaseCommon Stock | 30,000 | $5.78 | $173,541.00 |
DisclosureSEC source: 0001127602-20-010524 · form4.xml · nonDerivative · entry 1 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,324 F1 · price: Prices range from $5.7300 per share to $5.7900 per share. The reporting person undertakes to provide full pricing information if requested by the Securities and Exchange Commission, the issuer or a security holder of the issuer. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 11:01 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | PurchaseCommon Stock | 10,000 | $7.65 | $76,546.00 |
DisclosureSEC source: 0001127602-20-007112 · form4.xml · nonDerivative · entry 1 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,324 F1 · price: Prices range from $7.6400 per share to $7.6700 per share. The reporting person undertakes to provide full pricing information if requested by the Securities and Exchange Commission, the issuer or a security holder of the issuer. Read SEC document |
| November 08, 2019 Filed Nov 12, 2019 08:08 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | PurchaseCommon Stock | 20,000 | $7.73 | $154,588.00 |
DisclosureSEC source: 0001127602-19-032417 · form4.xml · nonDerivative · entry 1 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,324 F1 · price: Prices range from $7.7104 per share to $7.7700 per share. The reporting person undertakes to provide full pricing information if requested by the Securities and Exchange Commission, the issuer or a security holder of the issuer. Read SEC document |
| November 05, 2019 Filed Nov 7, 2019 15:03 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantStock Options (Right to Buy) · Derivative | 198,119 | $0.00 Strike: $10.10 | $0.00 |
DisclosureSEC source: 0001127602-19-032143 · form4.xml · derivative · entry 2 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,119 Underlying: Common Stock · 198,119 shares Expires 2029-11-05 F2 · shares: This award is made under the 2012 Stock Incentive Plan pursuant to Mr. Kenny's Amended and Restated Employment Agreement effective October 1, 2019. The options vest on a pro rata basis over the three (3) years following the Agreement's effective date. F3 · derivative.exercise_date: These options vest on a pro rata basis over the three (3) years following the October 1, 2019 effective date of Mr. Kenny's Amended and Restated Employment Agreement. Read SEC document |
| November 05, 2019 Filed Nov 7, 2019 15:03 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantCommon Stock | 99,505 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-032143 · form4.xml · nonDerivative · entry 1 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,324 F1 · shares: This award is made under the 2012 Stock Incentive Plan pursuant to Mr. Kenny's Amended and Restated Employment Agreement effective October 1, 2019. The restricted stock units vest in full (100%) on October 1, 2022. Read SEC document |
| October 11, 2019 Filed Oct 15, 2019 09:29 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Tax withholdingCommon Stock | 4,181 | $8.83 | $36,918.23 |
DisclosureSEC source: 0001127602-19-030443 · form4.xml · nonDerivative · entry 1 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,819 Read SEC document |
| May 08, 2019 Filed May 9, 2019 12:40 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | PurchaseCommon Stock | 20,000 | $11.49 | $229,744.00 |
DisclosureSEC source: 0001127602-19-017855 · form4.xml · nonDerivative · entry 1 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,000 F1 · price: Prices range from $11.4410 per share to $11.5100 per share. The reporting person undertakes to provide full pricing information if requested by the Securities and Exchange Commission, the issuer or a security holder of the issuer. Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 12:48 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-033646 · form4.xml · nonDerivative · entry 1 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,000 F1 · shares: These restricted stock units are awarded under the 2012 Stock Incentive Plan and vest in full (100%) on November 15, 2021. Read SEC document |
| November 08, 2017 Filed Nov 13, 2017 15:41 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-031881 · form4.xml · nonDerivative · entry 1 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,000 F1 · shares: These restricted stock units are awarded under the 2012 Stock Incentive Plan and vest in full (100%) on November 15, 2021. Read SEC document |
| October 09, 2017 Filed Oct 11, 2017 19:07 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $14.50 | $0.00 |
DisclosureSEC source: 0000899243-17-024070 · doc4.xml · derivative · entry 2 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-10-09 F2 · derivative.exercise_date: These options vest in four equal annual installments from the date of grant (i.e., 25% per year until fully vested on October 9, 2021). Read SEC document |
| October 09, 2017 Filed Oct 11, 2017 19:07 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantCommon Stock | 13,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-024070 · doc4.xml · nonDerivative · entry 1 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 F1 · shares: These Restricted Stock units vest in full on October 9, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.